Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1992-3-24
|
pubmed:abstractText |
Factor AF2, a now standardized extract from liver and spleen of newborn lambs, showed myeloprotective capacity on platelet- and erythrocyte-count as well as on hemoglobinconcentration in patients undergoing aggressive chemotherapy. In addition, a possible influence on prolonged remission duration in patients with mammary carcinoma had been claimed. In this study, the effect of Factor AF2 on mitogen-induced interferon-gamma release by PBMC was tested in 23 healthy humans and in 23 tumor patients. All patients were prior to surgery and had not yet received radio- or chemotherapy at the time of examination. The interferon-gamma concentration of the supernatants was measured using an enzyme-linked immunosorbent assay (ELISA). The cells were stimulated with PHA at 7.5 micrograms/ml. In the reference group, interferon-gamma concentration rose to 26 units/ml and to 15.5 units/ml in the tumor patients. In the reference persons, an addition of Factor AF2 at concentrations from 10(1) micrograms/ml to 10(3) micrograms/ml resulted in a small non-significant decrease of interferon-gamma release. At 10(4) micrograms/ml, neither test group showed measurable interferon-gamma concentration. In the tumor patients, cocultivation with Factor AF2 until concentration of 10(2) micrograms/ml resulted in a dose-dependent increase of interferon-gamma release, where 20.5 units/ml interferon-gamma were reached. At 10(3) micrograms/ml, Factor AF2 showed no effect on interferon-gamma release compared with the stimulation with mitogen alone. Flow-cytometry analysis of CD3, CD4, CD8, CD16, CD19, CD56, and HLA-DR expression of the PBMC deriving either from reference persons or from patients revealed an almost identical distribution. A slight difference in CD16-positive and HLA-DR positive cells, respectively, was not significant.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Inducers,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Phytohemagglutinins,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/factor AF2
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-9130
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
191
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
281-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:1788474-Adjuvants, Immunologic,
pubmed-meshheading:1788474-Adult,
pubmed-meshheading:1788474-Aged,
pubmed-meshheading:1788474-Aged, 80 and over,
pubmed-meshheading:1788474-Antigens, CD,
pubmed-meshheading:1788474-Cells, Cultured,
pubmed-meshheading:1788474-Female,
pubmed-meshheading:1788474-HLA-DR Antigens,
pubmed-meshheading:1788474-Humans,
pubmed-meshheading:1788474-Interferon Inducers,
pubmed-meshheading:1788474-Interferon-gamma,
pubmed-meshheading:1788474-Leukocytes, Mononuclear,
pubmed-meshheading:1788474-Lymphocyte Activation,
pubmed-meshheading:1788474-Male,
pubmed-meshheading:1788474-Middle Aged,
pubmed-meshheading:1788474-Neoplasms,
pubmed-meshheading:1788474-Phytohemagglutinins,
pubmed-meshheading:1788474-Secretory Rate,
pubmed-meshheading:1788474-Stimulation, Chemical,
pubmed-meshheading:1788474-Tissue Extracts
|
pubmed:year |
1991
|
pubmed:articleTitle |
Improvement of impaired mitogen-induced interferon-gamma release of peripheral blood mononuclear cells derived from tumor patients by Factor AF2.
|
pubmed:affiliation |
Medizinische Klinik der Ruhruniversität Bochum, St. Josef Hospital, Federal Republic of Germany.
|
pubmed:publicationType |
Journal Article
|